Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600211 Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
94 GF Score
Price ¥36.42
GF Value ¥39.85
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Tibet Rhodiola Pharmaceutical Holding Co  (SHSE:600211) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PS Ratio Related Terms


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PS Ratio Chart

Tibet Rhodiola Pharmaceutical Holding Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.21 5.29 6.76 6.49 7.03

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.27 7.90 6.94 6.40 5.74

SHSE:600211 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted PS Ratio falls into.


SHSE:600211
94GF Score
Tibet Rhodiola Pharmaceutical Holding Co SHSE:600211
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tibet Rhodiola Pharmaceutical Holding Co Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Tibet Rhodiola Pharmaceutical Holding Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Tibet Rhodiola Pharmaceutical Holding Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.61/116.0564*116.0564
=2.610

Current CPI (Jun. 2026) = 116.0564.

Tibet Rhodiola Pharmaceutical Holding Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.906 102.400 1.027
201612 1.149 102.600 1.300
201703 0.927 103.200 1.042
201706 0.581 103.100 0.654
201709 0.634 104.100 0.707
201712 0.835 104.500 0.927
201803 0.651 105.300 0.717
201806 0.734 104.900 0.812
201809 0.882 106.600 0.960
201812 0.877 106.500 0.956
201903 0.909 107.700 0.980
201906 0.998 107.700 1.075
201909 0.969 109.800 1.024
201912 1.007 111.200 1.051
202003 0.910 112.300 0.940
202006 1.029 110.400 1.082
202009 1.120 111.700 1.164
202012 1.190 111.500 1.239
202103 1.534 112.662 1.580
202106 1.687 111.769 1.752
202109 1.626 112.215 1.682
202112 1.789 113.108 1.836
202203 2.009 114.335 2.039
202206 2.103 114.558 2.131
202209 1.908 115.339 1.920
202212 1.851 115.116 1.866
202303 2.814 115.116 2.837
202306 2.834 114.558 2.871
202309 1.699 115.339 1.710
202312 2.378 114.781 2.404
202403 2.163 115.227 2.179
202406 2.825 114.781 2.856
202409 1.740 115.785 1.744
202412 1.959 114.893 1.979
202503 2.209 115.116 2.227
202506 2.912 114.907 2.941
202509 1.361 115.471 1.368
202512 2.768 115.832 2.773
202603 2.245 116.303 2.240
202606 2.610 116.056 2.610

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Tibet Rhodiola Pharmaceutical Holding Co (SHSE:600211) Overvalued in 2026?

Based on GuruFocus' analysis, Tibet Rhodiola Pharmaceutical Holding Co stock appears to be undervalued. The current stock price of ¥36.42 is trading 8.6% below its estimated GF Value™ of ¥39.85. GuruFocus considers Tibet Rhodiola Pharmaceutical Holding Co to be Fairly Valued.

Key valuation signals for SHSE:600211:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ¥39.85 vs. price of ¥36.42 (8.6% below fair value)
  • GF Score™: 94/100 with 3 warning signs

No single metric tells the full story. See the SHSE:600211 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tibet Rhodiola Pharmaceutical Holding Co Business Description

Address No. 3 Guangzhou Road, Area A, Lhasa Economic and Technological Development Zone, Tibet Autonomous Region, Lhasa, CHN, 850000
Tibet Rhodiola Pharmaceutical Holding Co is a pharmaceutical company engaged in the production and sales of capsules, biological agents, granules, and coatings. The company's products cover biopharmaceuticals, Tibetan medicine, traditional Chinese medicine, and chemical drugs, involving fields such as cardiovascular and cerebrovascular diseases, hepatobiliary diseases, orthopedic pain relief, rheumatism, and cold medicines.
94GF Score

Get the complete analysis for SHSE:600211

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥36.42
Price
¥39.85
GF Value